UK regulator approves orforglipron tablet for weight and diabetes
The MHRA authorised orforglipron (Foundayo) on 10 August 2026, the first European approval of an oral GLP-1 tablet for weight management and type 2 diabetes. It is authorised for adults with specified BMI thresholds and for glycaemic control in insufficiently controlled type 2 diabetes. The tablet is once daily with no food restrictions and dose escalation begins at 0.8 mg up to 17.2 mg with at least one month per dose step. Common side effects include nausea, constipation and diarrhoea. The medicine is prescription only, not yet available via the NHS, and will face NICE evaluation and ongoing MHRA monitoring.
MHRA authorised an oral GLP-1 tablet for obesity and type 2 diabetes.
Context
The MHRA has authorised orforglipron as a new oral GLP-1 medicine. Next, NICE will…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorPotential upward pressure on NHS drug…Locked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsNICE technology appraisal decision and…Locked
- Probability of ChangeLocked
- Debate PointsLocked
- Follow-up QuestionsWill the National Institute for Health…Locked
- Pros & ConsPatients: they may gain an oral…Locked
Free account — 3 full analyses a day, no card.